---
title: "VK2735 in Chronic weight management: VK2735-101 subcutaneous parts A and B"
description: "Formulary evidence on VK2735 in Chronic weight management: VK2735-101 subcutaneous parts A and B. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 49 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/vk2735-101-subcutaneous-parts-a-and-b"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VK2735-101 subcutaneous parts A and B

<a id="heading-3.1.9"></a>

## 3.1.9 VK2735-101 Subcutaneous Parts A and B

<a id="heading-3.1.9.1"></a>

### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

#### Safety, tolerability, and dose identification as primary objectives

> “The primary objectives of the study were to evaluate the safety and tolerability of single and multiple doses of VK2735 administered subcutaneously and identify suitable doses for further clinical development. The secondary objective was to evaluate the pharmacokinetics of VK2735 in healthy subjects.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.1-2"></a>

#### Exploratory pharmacodynamic assessments of body weight and liver fat

> “Exploratory pharmacodynamic assessments include evaluations of changes in body weight and liver fat content after four weeks of once-weekly administration.”

Source: [Viking Therapeutics phase 1 initiation release (2022)](https://ir.vikingtherapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist)

<a id="topic-3.1.9.1-3"></a>

#### First administration to humans and nonalcoholic steatohepatitis as the initial target

> “This study will be the first time the test medication, VK2735 is given to humans.”
> “Viking Therapeutics Inc. is developing VK2735 as a potential treatment for nonalcoholic steatohepatitis (NASH).”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.1-4"></a>

#### Study objectives in the ISRCTN record

> “The purpose of the present study is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 administered subcutaneously (SC) in healthy adults and otherwise healthy adults who have an increased body mass index.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.2"></a>

### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

#### Initiation in January 2022

> “SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735”

Source: [Viking Therapeutics phase 1 initiation release (2022)](https://ir.vikingtherapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist)

<a id="topic-3.1.9.2-2"></a>

#### Single centre in Adelaide, Australia, in the ISRCTN record

| Field | Registry value |
| --- | --- |
| Countries of recruitment | “Australia” |
| Study participating centre | “Cmax Clinical Research Pty Ltd” |
| Date of first enrolment | “01/12/2021” |
| Date of final enrolment | “01/06/2023” |
| Planned study period | “December 2021 to December 2022” |

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.2-3"></a>

#### Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Study start (actual) | “2021-12-14” |
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site | “Viking Clinical Site” |
| Site city | “Adelaide” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.2-4"></a>

#### Results announced in March 2023 and presented at ObesityWeek 2023

> “SAN DIEGO, March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

> “SAN DIEGO, Oct. 17, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were featured in an oral presentation at ObesityWeek 2023”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.3"></a>

### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

#### Randomized, double-blind, placebo-controlled single and multiple ascending dose design

> “The Phase 1 trial was a randomized, double-blind, placebo-controlled SAD and MAD study in healthy adults. The SAD portion of the study evaluated VK2735 in healthy adults, while the MAD portion of the study enrolled healthy adults with a minimum body mass index of 30 kilograms per meter squared.”
> “The SAD portion of the study evaluated escalating single doses of VK2735. In the MAD portion of the study subjects received VK2735 once weekly for 28 days.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.3-2"></a>

#### Parts A and B and safety review before dose escalation in the ClinicalTrials.gov record

> “Part A (Single Ascending Dose [SAD]) will be conducted to assess the safety, tolerability, and PK profile in healthy participants following 1 single SC injection of VK2735 or VK2735 matching placebo (SAD Cohort 1 through SAD Cohort 6).”
> “Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part A (SAD), Part B (MAD), and Part C (MAD-PO) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort.”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.3-3"></a>

#### Cohorts and 3:1 randomization in the ISRCTN record

> “Up to 48 participants will be enrolled into 6 groups (8 participants in each) who will receive a single dose of the drug. Participants in each of the 6 groups will receive a dose higher than the previous group.”
> “Approximately 40 Part B (MAD) participants will enrol into one of 5 MAD cohorts (MAD Cohort 1 through MAD Cohort 5, N = 8 per cohort) and will be randomized to receive either VK2735 or matching VK2735 placebo at a ratio of 3:1 (6 VK2735:2 placebo per cohort).”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.3-4"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Official title | “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index” |
| Other study ID | “VK2735-101” |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.3-5"></a>

#### Study design in the ISRCTN record

> “Single-center randomized double-blind placebo-controlled single and multiple ascending dose study”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.4"></a>

### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

#### Healthy adults in Part A and adults with a body mass index of at least 30 kg/m2 in Part B

> “The SAD portion of the study evaluated VK2735 in healthy adults, while the MAD portion of the study enrolled healthy adults with a minimum body mass index of 30 kilograms per meter squared.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.4-2"></a>

#### Participants and age range in the ISRCTN record

> “Healthy volunteers, and otherwise healthy volunteers who have an increased body mass index, between the ages of 18 and 65 years.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.4-3"></a>

#### Key inclusion criteria in the ISRCTN record

> “Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator”
> “Participant body weight must have been stable (no change greater than 5%) for a minimum 8 weeks prior to Screening”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.4-4"></a>

#### Key exclusion criteria in the ISRCTN record

> “History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant”
> “Have serum triglycerides >5.65 mmol/l (500 mg/dl) at Screening”
> “Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or HIV”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.5"></a>

### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

#### Subcutaneous formulation: single ascending doses in Part A

> “Approximately 48 Part A (SAD) participants will enroll into one of 6 SAD cohorts (SAD Cohort 1 through SAD Cohort 6, N = 8 per cohort) and will be randomized to receive either VK2735 (at doses: 0.25 mg, 0.5 mg, 1.0 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg) or VK2735 matching placebo at a ratio of 3:1 (6 VK2735:2 placebo per cohort).”
> “Participants in Part A (SAD) (ie, SAD Cohort 1 through SAD Cohort 6) will receive a single dose SC injection in any upper quadrant of the abdomen of VK2735 or placebo on Day 1 after a minimum 8 hour fast.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.5-2"></a>

#### Subcutaneous formulation: once-weekly multiple ascending doses for 4 weeks in Part B

> “Participants in Part B (MAD) cohorts will receive a single SC injection of VK2735 or matching VK2735 placebo administered once weekly for 4 consecutive weeks. Doses will be administered clockwise around the abdomen following a minimum 8 hour fast on Day 1, Day 8, Day 15, and Day 22.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.5-3"></a>

#### Subcutaneous formulation: weekly dose levels in the multiple ascending dose cohorts

| Cohort | Dose level |
| --- | --- |
| Cohort 1 | “VK2735 0.5 mg” |
| Cohort 2 | “VK2735 1.5 mg” |
| Cohort 3 | “VK2735 1.5/3/5/5 mg” |
| Cohort 4 | “VK2735 3/5/5/7.5 mg” |
| Cohort 5 | “VK2735 5/5/7.5/10 mg” |
| Escalation in cohort 3 | “Subjects received escalating weekly doses of 1.5 mg, 3.0 mg, 5.0 mg, 5.0 mg.” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.5-4"></a>

#### Subcutaneous formulation: arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “Placebo (Part A)” | “Placebo administered SC once in healthy participants” |
| “VK2735 (Part A)” | “Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.” |
| “Placebo (Part B)” | “Placebo administered SC once weekly for four weeks in healthy participants” |
| “VK2735 (Part B)” | “Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.9.6"></a>

### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

#### 3.1.9.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

##### Registered primary and secondary outcome measures in ClinicalTrials.gov

| Outcome | Measure | Description | Time frame |
| --- | --- | --- | --- |
| Primary | “Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)” | “To evaluate the safety and tolerability of single doses of subcutaneous injections of VK2735 in healthy participants” | “8 days” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK2735” | “Pharmacokinetic profile of VK2735 by measuring peak plasma concentration (Cmax)” | “29 days” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.6.1-2"></a>

##### Primary and key secondary outcome measures in the ISRCTN record

> “Safety measured as the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) measured between baseline and 16 days for part A of the study, and between baseline and 43 days for part B of the study”
> “Plasma pharmacokinetic analysis of VK2735 measured using Cmax, Tmax, AUC, and other plasma PK analysis of VK2735 from blood samples taken between 30 min pre-dose and 168 h post-dose for part A and part B of the study”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.7"></a>

### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

#### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

##### Target sample size in the ISRCTN record

> “Target sample size at registration”
> “88”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Enrollment (actual) | “92” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.7.1-3"></a>

##### Participants analyzed in the multiple ascending dose cohorts

| Group | Participants analyzed for body weight |
| --- | --- |
| Placebo | “(n=10)” |
| VK2735 0.5 mg | “(n=6)” |
| VK2735 1.5 mg | “(n=6)” |
| VK2735 1.5/3/5/5 mg | “(n=7)” |
| VK2735 3/5/5/7.5 mg | “(n=6)” |
| VK2735 5/5/7.5/10 mg | “(n=6)” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.7.1-4"></a>

##### Participants analyzed for liver fat

| Group | Participants analyzed | Subset with nonalcoholic fatty liver disease |
| --- | --- | --- |
| Placebo | “(n=8)” | “n=3” |
| VK2735 0.5 mg | “(n=6)” | “n=0” |
| VK2735 1.5 mg | “(n=6)” | “n=4” |
| VK2735 1.5/3/5/5 mg | “(n=6)” | “n=4” |
| VK2735 3/5/5/7.5 mg | “(n=6)” | “n=4” |
| VK2735 5/5/7.5/10 mg | “(n=4)” | “n=1” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.7.2"></a>

#### 3.1.9.7.2 Description of Analysis Sets

<a id="topic-3.1.9.7.2-1"></a>

##### Statistical methods for body weight

> “Least squares mean.”
> “Two-sided t test using mixed model for repeated measures.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.7.2-2"></a>

##### Statistical methods for liver fat

> “MRI-PDFF; all subjects enrolled in MAD portion of study were required to have baseline BMI ≥30 kg/m2.”
> “Two-sided t test using ANCOVA.”
> “In the subgroup of study subjects with non-alcoholic fatty liver disease (NAFLD), defined as those with greater than 5% liver fat at baseline, the reductions in liver fat levels were more pronounced.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.8"></a>

### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

#### 3.1.9.8.1 Participant Disposition

<a id="topic-3.1.9.8.1-1"></a>

##### No discontinuations for gastrointestinal adverse events in the multiple ascending dose cohorts

> “No subjects were discontinued for nausea, vomiting, or GI adverse events.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="heading-3.1.9.8.2"></a>

#### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

##### Mean baseline body weight in the multiple ascending dose cohorts

| Group | Mean baseline body weight (kg) |
| --- | --- |
| Placebo (n=10) | “121.1” |
| VK2735 0.5 mg (n=6) | “101.2” |
| VK2735 1.5 mg (n=6) | “114.8” |
| VK2735 1.5/3/5/5 mg (n=7) | “115.3” |
| VK2735 3/5/5/7.5 mg (n=6) | “116.3” |
| VK2735 5/5/7.5/10 mg (n=6) | “95.9” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.2-2"></a>

##### Mean baseline liver fat content in the multiple ascending dose cohorts

| Group | Mean baseline liver fat content (%) |
| --- | --- |
| Placebo (n=8) | “6.59” |
| VK2735 0.5 mg (n=6) | “2.58” |
| VK2735 1.5 mg (n=6) | “7.84” |
| VK2735 1.5/3/5/5 mg (n=6) | “8.14” |
| VK2735 3/5/5/7.5 mg (n=6) | “11.1” |
| VK2735 5/5/7.5/10 mg (n=4) | “3.96” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.8.3"></a>

#### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

##### Subcutaneous formulation: pharmacokinetics after single doses

> “In the SAD portion of the study, VK2735 demonstrated promising safety and tolerability, as well as a predictable pharmacokinetic (PK) profile. Following single subcutaneous doses, VK2735 demonstrated a half-life of approximately 170 to 250 hours, a Tmax (time to reach maximum plasma concentration) ranging from approximately 75 to 90 hours, and excellent therapeutic exposures.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.3-2"></a>

##### Subcutaneous formulation: pharmacokinetic summary in the corporate presentation

> “Tmax ~72 hours, gradual onset; T1/2 170 – 253 hours, amenable to weekly dosing”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.9.8.3-3"></a>

##### Body weight after 28 days of weekly dosing

> “In the 28-day MAD portion of the study, VK2735 demonstrated encouraging tolerability and positive signs of clinical activity. All cohorts receiving VK2735 demonstrated reductions in mean body weight from baseline, ranging up to 7.8%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 6.0%. Statistically significant differences compared to placebo were maintained or improved at the Day 43 follow-up time point, 21 days after the last dose of VK2735 was administered.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.3-4"></a>

##### Change in body weight by multiple ascending dose cohort at day 28

| Measure | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
| --- | --- | --- | --- | --- | --- | --- |
| Mean change from baseline body weight | “-2.2 kg” | “-2.6 kg” | “-4.1 kg” | “-4.5 kg” | “-8.2 kg” | “-7.6 kg” |
| Mean percent change from baseline | “-1.8 %” | “-2.5 %” | “-3.7 %” | “-4.1 %” | “-7.4 %” | “-7.8 %” |
| Placebo-adjusted mean change from baseline | “-” | “-0.7 %” | “-1.9 %” | “-2.3 %” | “-5.6 %” | “-6.0 %” |
| p-value vs. placebo | “-” | “0.64” | “0.17” | “0.09” | “0.0003” | “0.0002” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.3-5"></a>

##### Durability of weight loss after the last dose

> “Durable weight loss observed, >90% of efficacy retained 4 weeks after last dose”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.9.8.3-6"></a>

##### Conclusions of the ObesityWeek 2023 abstract

> “VK2735 is a novel long-acting dual agonist of the GLP-1 and GIP receptors that has demonstrated reductions in body weight, glucose, and plasma lipids in animal models.”
> “VK2735 demonstrated promising safety, tolerability, and predictable pharmacokinetics in this study. Cohorts receiving VK2735 also demonstrated encouraging reductions in body weight following 28 days of weekly dosing. A Phase 2 study in patients with obesity is planned.”

Source: [Lian et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1002/oby.23938)

<a id="topic-3.1.9.8.3-7"></a>

##### Liver fat after 28 days of weekly dosing

> “Following 28 days of once-weekly treatment with VK2735, study results demonstrated reductions in liver fat content, both as compared to baseline and as compared to placebo. Subjects receiving VK2735 experienced reductions in liver fat ranging up to 47.2% from baseline.”
> “For these subjects, reductions from baseline after four weekly doses ranged up to 49.7%, and placebo-adjusted reductions of up to 58.5% were reported.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-3.1.9.8.3-8"></a>

##### Change in liver fat content by multiple ascending dose cohort

| Measure | Placebo | 0.5 mg | 1.5 mg | 1.5/3/5/5 mg | 3/5/5/7.5 mg | 5/5/7.5/10 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Mean percent change from baseline, all participants | “-0.7” | “3.9” | “-24.2” | “-24.0” | “-47.2” | “-8.4” |
| p-value vs. placebo, all participants | “-” | “0.74” | “0.09” | “0.10” | “0.002” | “0.62” |
| Mean percent change from baseline, nonalcoholic fatty liver disease subset | “8.8” | “-” | “-33.8” | “-32.5” | “-49.7” | “-10.7” |
| p-value vs. placebo, nonalcoholic fatty liver disease subset | “-” | “-” | “0.03” | “0.03” | “0.006” | “-” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-3.1.9.8.3-9"></a>

##### Plasma lipids after 28 days of weekly dosing

> “Dose dependent reductions from baseline in these plasma lipid levels were observed across VK2735 treatment cohorts after four weekly doses. No meaningful changes in levels of high-density lipoprotein cholesterol (HDL-C) were observed following treatment with VK2735.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-3.1.9.8.3-10"></a>

##### Change in plasma lipids by multiple ascending dose cohort

| Measure | Placebo (n=9) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=6) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=4) |
| --- | --- | --- | --- | --- | --- | --- |
| Mean change in apolipoprotein B from baseline (%) | “1.8” | “3.3” | “-1.8” | “-12.9” | “-12.5*” | “-20.5” |
| Mean change in LDL-C from baseline (%) | “-9.5” | “1.4” | “-10.6” | “-13.7” | “-20.3*” | “-23.0” |
| Mean change in total cholesterol from baseline (%) | “-5.1” | “-1.7” | “-10.8” | “-14.9*” | “-17.4*” | “-21.0” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

> “Notes: *p<0.05 vs. baseline.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.8.4"></a>

#### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

#### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

##### Tolerability of single doses

> “Well tolerated up to 7.5 mg single doses”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.9.8.5-2"></a>

##### Adverse events after repeated weekly dosing

> “VK2735 demonstrated encouraging safety and tolerability following repeated dosing. The majority of observed adverse events (98%) were reported as mild or moderate. The majority of gastrointestinal (GI) related adverse events (99%) were also reported as mild or moderate. One serious adverse event (SAE) was reported in a subject receiving VK2735. A subject with a history of cholelithiasis (gallstones) experienced an SAE of acute choledocholithiasis (gallstone obstruction). Nausea was reported among subjects receiving both VK2735 (58%) and placebo (50%). Among subjects receiving VK2735, the majority of reported nausea (89%) was characterized as mild (11% moderate). Vomiting was reported in 6/31 (19%) VK2735 treated subjects and 1/10 (10%) subjects receiving placebo.”
> “Despite robust activation of the incretin receptor pathways, no hypoglycemia was reported.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.5-3"></a>

##### Commonly reported adverse events by multiple ascending dose cohort

| Event | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
| --- | --- | --- | --- | --- | --- | --- |
| Nausea, mild | “5 (50%)” | “2 (33%)” | “4 (67%)” | “4 (57%)” | “5 (83%)” | “1 (17%)” |
| Nausea, moderate | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “1 (17%)” |
| Vomiting | “1 (10 %)” | “2 (33 %)” | “0 (0 %)” | “2 (29 %)” | “1 (17 %)” | “1 (17 %)” |
| Diarrhea | “3 (30 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “0 (0 %)” | “0 (0 %)” |
| Constipation | “0 (0 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “1 (17 %)” | “0 (0 %)” |
| Decreased appetite | “3 (30 %)” | “3 (50 %)” | “3 (50 %)” | “4 (57 %)” | “5 (83 %)” | “6 (100 %)” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.5-4"></a>

##### Higher doses expected to need longer titration

> “The company believes tolerability data from this study indicate that higher doses may be achieved with longer titration windows.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="heading-3.1.9.9"></a>

### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

#### Summary: study limitations

VK2735-101 Parts A and B were the first administration of VK2735 to humans, conducted at a single centre in Adelaide, Australia, in healthy adults (Part A) and otherwise healthy adults with a body mass index of at least 30 kg/m2 (Part B). The registered primary endpoint was the incidence of treatment-emergent adverse events, and body weight, liver fat, and lipids were exploratory pharmacodynamic measures. The multiple ascending dose part dosed participants once weekly for 4 weeks, with 6 or 7 participants in each VK2735 cohort and 10 receiving placebo, and the highest weekly dose (10 mg) is lower than the doses later carried into phase 2 and phase 3. The liver fat subgroup with nonalcoholic fatty liver disease contained 0 to 4 participants per cohort. Single-dose results by dose level, participant disposition, and baseline characteristics other than body weight and liver fat were not reported. The ISRCTN record named nonalcoholic steatohepatitis as the condition VK2735 was being developed for and a target sample size of 88; the ClinicalTrials.gov record reports an actual enrollment of 92 for Parts A, B, and C combined, whereas the oral first-in-human poster reports that 92 participants were randomized in the oral part alone. The two documents also differ on the time to maximum concentration (approximately 75 to 90 hours in the results release and about 72 hours in the corporate presentation). Results are available only in press releases, a corporate presentation, and a congress abstract, with no peer-reviewed full publication and no results posted to either registry.

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018); [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237); [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735); [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Lian et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1002/oby.23938); [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.9.9-2"></a>

#### Limited exposure to higher doses

> “Though subjects in this study were only exposed to higher doses for a limited time, no signs of plateau were observed.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.9-3"></a>

#### Intention to publish date moved in the ISRCTN record

> “The intention to publish date was changed from 01/12/2025 to 01/06/2026.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
